Form 4: Teva Pharmaceutical Industries Director Amir Elstein Reports Share Activity

Director Amir Elstein reports the vesting and subsequent disposal of restricted share units resulting in the acquisition of ordinary shares.

Summary

• Amir Elstein, a director of Teva Pharmaceutical Industries Ltd., reported a transaction on June 15, 2024.
• The transaction involved the vesting of 21,108 restricted share units, which converted into ordinary shares.
• Following the transaction, Elstein directly owns 2,094,331 ordinary shares.

Sentiment

Score: 5

Explanation: This is a standard regulatory filing reflecting routine compensation practices; it doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and share ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages including restricted share units are a common practice among publicly traded pharmaceutical companies like Teva, Novartis, and Pfizer.
• Vesting schedules and terms are typically aligned with industry benchmarks to incentivize long-term performance and retention.
• Form 4 filings are standard regulatory requirements for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with securities laws.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it reflects standard executive compensation practices.
• Employees may view the vesting of share units as a positive sign of the company's commitment to its leadership.

Key Dates